Replies to post #1253 on Enanta Pharmaceuticals Inc (ENTA)

[NY1972]

No Ribavirin on top of 1 pill for GT 1b. 100% SVR12

Enanta Pharmaceuticals Announces the U.S. FDA Grants Priority Review to AbbVie’s Supplemental New Drug Application for VIEKIRA PAK® Without Ribavirin in Genotype 1B Chronic Hepatitis C Virus Patients with Compensated Cirrhosis
TURQUOISE-III study showed 100 percent sustained virologic response at 12 weeks post-treatment (SVR12) in patients with genotype 1b (GT1b) chronic hepatitis C virus and compensated cirrhosis (Child-Pugh A)

AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK

[DewDiligence]

CSO exercised and held more options yesterday: #msg-119968598.